Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations

Abstract Background Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a systematic review of these studies to highlight the effect th...

Full description

Bibliographic Details
Main Authors: Daniel R. Morales, Jim Slattery, Stephen Evans, Xavier Kurz
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12916-017-0993-3
_version_ 1811229100278284288
author Daniel R. Morales
Jim Slattery
Stephen Evans
Xavier Kurz
author_facet Daniel R. Morales
Jim Slattery
Stephen Evans
Xavier Kurz
author_sort Daniel R. Morales
collection DOAJ
description Abstract Background Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a systematic review of these studies to highlight the effect that important methodological limitations have on such analyses and to consider approaches to the conduct, reporting and interpretation of future studies. Methods A review of MEDLINE and EMBASE identified case–control, cohort and sibling studies assessing the risk of ASD and ADHD with antidepressant use during pregnancy. Approaches to confounding adjustment were described. Crude and adjusted effect estimates for comparisons between antidepressant exposure during pregnancy vs. all unexposed women were first meta-analysed using a generic inverse variance method of analysis, followed by effect estimates for alternative pre-selected comparison groups. Results A total of 15 studies measuring ASD as an outcome (involving 3,585,686 children and 40,585 cases) and seven studies measuring ADHD as an outcome (involving 2,765,723 patients and 52,313 cases) were identified. Variation in confounding adjustment existed between studies. Updated effect estimates for the association between maternal antidepressant exposure during pregnancy vs. all unexposed women remained statistically significant for ASD (adjusted random-effects risk ratio [RaRR] 1.53, 95% confidence interval [CI] 1.31–1.78). Similar significant associations were observed using pre-pregnancy maternal antidepressant exposure (RaRR 1.48, 95% CI 1.29–1.71) and paternal antidepressant exposure during pregnancy (1.29, 95% CI 1.08–1.53), but analyses restricted to using women with a history of affective disorder (1.18, 95% CI 0.91–1.52) and sibling studies (0.96, 95% CI 0.65–1.42) were not statistically significant. Corresponding associations for risk of ADHD with exposure were: RaRR 1.38, 95% CI 1.13–1.69 (during pregnancy), RaRR 1.38, 95% CI 1.14–1.69 (during pre-pregnancy), RaRR 1.71, 95% CI 1.31–2.23 (paternal exposure), RaRR 0.98, 95% CI 0.77–1.24 (women with a history of affective disorder) and RaRR 0.88, 95% CI 0.70–1.11 (sibling studies). Conclusions Existing observational studies measuring the risk of ASD and ADHD with antidepressant exposure are heterogeneous in their design. Classical comparisons between exposed and unexposed women during pregnancy are at high risk of residual confounding. Alternative comparisons and sibling designs may aid the interpretation of causality and their utility requires further evaluation, including understanding potential limitations of undertaking meta-analyses with such data.
first_indexed 2024-04-12T10:08:47Z
format Article
id doaj.art-636402234e73490ca9a39d303dfba7e9
institution Directory Open Access Journal
issn 1741-7015
language English
last_indexed 2024-04-12T10:08:47Z
publishDate 2018-01-01
publisher BMC
record_format Article
series BMC Medicine
spelling doaj.art-636402234e73490ca9a39d303dfba7e92022-12-22T03:37:22ZengBMCBMC Medicine1741-70152018-01-0116111410.1186/s12916-017-0993-3Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerationsDaniel R. Morales0Jim Slattery1Stephen Evans2Xavier Kurz3Pharmacovigilance and Epidemiology Department, European Medicines Agency, 30 Churchill PlacePharmacovigilance and Epidemiology Department, European Medicines Agency, 30 Churchill PlaceDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, University of LondonPharmacovigilance and Epidemiology Department, European Medicines Agency, 30 Churchill PlaceAbstract Background Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a systematic review of these studies to highlight the effect that important methodological limitations have on such analyses and to consider approaches to the conduct, reporting and interpretation of future studies. Methods A review of MEDLINE and EMBASE identified case–control, cohort and sibling studies assessing the risk of ASD and ADHD with antidepressant use during pregnancy. Approaches to confounding adjustment were described. Crude and adjusted effect estimates for comparisons between antidepressant exposure during pregnancy vs. all unexposed women were first meta-analysed using a generic inverse variance method of analysis, followed by effect estimates for alternative pre-selected comparison groups. Results A total of 15 studies measuring ASD as an outcome (involving 3,585,686 children and 40,585 cases) and seven studies measuring ADHD as an outcome (involving 2,765,723 patients and 52,313 cases) were identified. Variation in confounding adjustment existed between studies. Updated effect estimates for the association between maternal antidepressant exposure during pregnancy vs. all unexposed women remained statistically significant for ASD (adjusted random-effects risk ratio [RaRR] 1.53, 95% confidence interval [CI] 1.31–1.78). Similar significant associations were observed using pre-pregnancy maternal antidepressant exposure (RaRR 1.48, 95% CI 1.29–1.71) and paternal antidepressant exposure during pregnancy (1.29, 95% CI 1.08–1.53), but analyses restricted to using women with a history of affective disorder (1.18, 95% CI 0.91–1.52) and sibling studies (0.96, 95% CI 0.65–1.42) were not statistically significant. Corresponding associations for risk of ADHD with exposure were: RaRR 1.38, 95% CI 1.13–1.69 (during pregnancy), RaRR 1.38, 95% CI 1.14–1.69 (during pre-pregnancy), RaRR 1.71, 95% CI 1.31–2.23 (paternal exposure), RaRR 0.98, 95% CI 0.77–1.24 (women with a history of affective disorder) and RaRR 0.88, 95% CI 0.70–1.11 (sibling studies). Conclusions Existing observational studies measuring the risk of ASD and ADHD with antidepressant exposure are heterogeneous in their design. Classical comparisons between exposed and unexposed women during pregnancy are at high risk of residual confounding. Alternative comparisons and sibling designs may aid the interpretation of causality and their utility requires further evaluation, including understanding potential limitations of undertaking meta-analyses with such data.http://link.springer.com/article/10.1186/s12916-017-0993-3AutismAttention Deficit Hyperactivity DisorderPregnancyAntidepressantMeta-analysisEpidemiology
spellingShingle Daniel R. Morales
Jim Slattery
Stephen Evans
Xavier Kurz
Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
BMC Medicine
Autism
Attention Deficit Hyperactivity Disorder
Pregnancy
Antidepressant
Meta-analysis
Epidemiology
title Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
title_full Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
title_fullStr Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
title_full_unstemmed Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
title_short Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
title_sort antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder systematic review of observational studies and methodological considerations
topic Autism
Attention Deficit Hyperactivity Disorder
Pregnancy
Antidepressant
Meta-analysis
Epidemiology
url http://link.springer.com/article/10.1186/s12916-017-0993-3
work_keys_str_mv AT danielrmorales antidepressantuseduringpregnancyandriskofautismspectrumdisorderandattentiondeficithyperactivitydisordersystematicreviewofobservationalstudiesandmethodologicalconsiderations
AT jimslattery antidepressantuseduringpregnancyandriskofautismspectrumdisorderandattentiondeficithyperactivitydisordersystematicreviewofobservationalstudiesandmethodologicalconsiderations
AT stephenevans antidepressantuseduringpregnancyandriskofautismspectrumdisorderandattentiondeficithyperactivitydisordersystematicreviewofobservationalstudiesandmethodologicalconsiderations
AT xavierkurz antidepressantuseduringpregnancyandriskofautismspectrumdisorderandattentiondeficithyperactivitydisordersystematicreviewofobservationalstudiesandmethodologicalconsiderations